Theseus Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Theseus Pharmaceuticals

20/11/2023 12:01

* Theseus Pharmaceuticals Inc  THRX.OQ  reported a quarterly
adjusted loss of 31 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of -38 cents.  The mean expectation of
six analysts for the quarter was for a loss of 36 cents per
share. Wall Street expected results to range from -39 cents
to -32 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Theseus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 31 cents​.
    * The company reported a quarterly loss of $13.5 million.
    * Theseus Pharmaceuticals Inc shares had risen by 29.0% this
quarter and lost 30.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Theseus
Pharmaceuticals Inc is $7.00 
This summary was machine generated from LSEG data November 20 at
12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.36          -0.31          Beat
 Jun. 30 2023      -0.36          -0.34          Beat
 Mar. 31 2023      -0.42          -0.34          Beat
 Dec. 31 2022      -0.44          -0.35          Beat